18. June 2020 | 08:40 CET
BioNTech, Evotec, EXMceuticals - which stocks have the potential to double?
Experienced investors assume that the DAX, Germany's leading index, will still reach new highs in 2020. One of the best-known supporters of this scenario is the asset manager Dr. Jens Ehrhardt. Rising markets are supported by the measures taken by central banks and politicians - it is de facto the consequence of the increase in the money supply. This expected development will be of particular interest to those investors who have so far been on the sidelines and have to position themselves or reallocate.
time to read:
ISIN: CA30207T1049 , US09075V1026 , DE0005664809
Pessimists seldom have reason to be happy
At the stock exchange, buyer and seller meet. The buyer side sees potential, the seller side often has a different opinion. However, the motives for sales can also be detached from the question of the expected potential, for example, if the portfolio has become unbalanced or a stop-mark has been reached. Anyone who has been active on the stock market for a longer period of time and has been following the media closely has certainly already noticed that the optimists have reasons to be happy about a longer period and the pessimists can only ever feel confirmed in a relatively small but violent time window.
Central banks are pointing the way
For example, the DAX rose from 3,588 points in 2009 to 13,795 points in 2020 - a full 10,207 points. In the heat of the Corona battle, it went down to 8,255 points within four weeks starting in February, but at the current level of around 12,300 points, a new high is almost within reach again. The pessimists have now largely fallen silent again after their four-week celebration. The power of the central banks should not be underestimated.
Gateway to the EU market
If you want to participate in the future, you should take a look at EXMceuticals. The company signed a letter of intent last week with an operating subsidiary of Plena Global Holdings Inc, a major producer and supplier of medical grade cannabis ingredients. According to the agreement, the processing plant in Portugal planned by EXMceuticals will be supplied with GMP-compliant THC distillate in the future. With this agreement, EXMceuticals reinforces its strategy to position itself as the "gateway" to the European market for existing manufacturers of legal cannabis.
Europe as a growth market
"The demand will explode in the next few years as the European cannabis industry continues to develop into one of the largest cannabis markets in the world and more countries require the use of EU GMP standards. Securing valuable sources of ingredients with consistent, large-scale suppliers such as Plena Global is more important than ever for the buildout of the EXM supply chain. (...)," said Jonathan Summers, Chief Executive Officer of EXM.
Health in focus
BioNTech remains the focus of investors waiting for a vaccine against Covid-19. The team of experts cooperates with pharmaceutical giant Pfizer, among others. In addition, the company pursues the development of preparations and therapies for the individual treatment of cancer.
The active ingredient expert Evotec was also able to attract attention with positive reports in recent weeks. The company is participating in a project in the USA that is intended to enable the rapid assessment of potential health and environmental risks resulting from chemicals. In addition, a partnership was entered into for the development of antibodies against the immunodeficiency virus HIV. The US government has budgeted a volume of around USD 318 million for this project.